Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02452931 · ClinicalTrials.gov registry record · Phase 3
Study of Leuprolide Acetate Injectable Suspension in the Treatment of Central Precocious Puberty
A Phase 3 study of Precocious Puberty, Central, sponsored by Tolmar.
- Completed
- Registry status
- Phase 3
- Development phase
- 64
- Enrollment target
- 20
- Study locations
NCT02452931 is a Phase 3 study of Precocious Puberty, Central that has completed, run by Tolmar. The registered enrollment target is 64 participants. The trial reports 20 study locations across 13 states.
The verdict
NCT02452931, a Phase 3 study of Precocious Puberty, Central, has completed, sponsored by Tolmar.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 64 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study determines the effectiveness of leuprolide acetate 45 mg for injectable suspension for treatment of children with Central Precocious Puberty.
Conditions Studied
Interventions
- DRUG Leuprolide Acetate 45 mg
Study Locations (20)
Other
- Hospital de Ninos - Buenos Aires
- CHU de Quebec-Universite Laval - Québec
- Instituto de Investigaciones Aplicadas a la Neurociencia, A.C. - Durango
- The Liggins Institute, University of Auckland - Auckland
Florida
- Joe DiMaggio Children's Hospital - Hollywood
- Nemours Children's Clinic - Jacksonville
- Nemours Children's Hospital - Orlando
Washington
- Seattle Children's - Seattle
- MultiCare Institute for Research and Innovation - Tacoma
Santiago Metropolitan
- Pontificia Universidad Catolica de Chile - Santiago
- Instituto de Investigaciones Materno Infantil (IDIMI) - Santiago
California
- University of California, San Diego - San Diego
Indiana
- Riley Hospital for Children at Indiana University Health - Indianapolis
Minnesota
- University of Minnesota - Minneapolis
Ohio
- Cincinnati Children's Hospital Medical Center, Endocrine - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2015-08-31 |
| Est. Completion | 2018-09-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02452931
The ClinicalTrials.gov registry entry for NCT02452931 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tolmar, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Precocious Puberty, Central appearing as the primary indexed condition, and to 1 intervention - of which Leuprolide Acetate 45 mg is the first listed.
NCT02452931 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Other, Florida, Washington.
Frequently Asked Questions
What is clinical trial NCT02452931 about?
NCT02452931 is a clinical study titled "Study of Leuprolide Acetate Injectable Suspension in the Treatment of Central Precocious Puberty". This study determines the effectiveness of leuprolide acetate 45 mg for injectable suspension for treatment of children with Central Precocious Puberty.
What is the current status of trial NCT02452931?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 64 participants. The study started on 2015-08-31. Estimated completion is 2018-09-05.
What conditions does trial NCT02452931 study?
This clinical trial studies the following conditions: Precocious Puberty, Central.
What interventions are being tested in trial NCT02452931?
The interventions under investigation include: Leuprolide Acetate 45 mg (DRUG).
Who is sponsoring clinical trial NCT02452931?
This trial is sponsored by Tolmar, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02452931 being conducted?
This trial has 20 study locations across California, Florida, Indiana, Minnesota, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.